Dimitris Mathianakis

Economist - Professor - Investor

[Shay Boloor @StockSavvyShay]

10 stocks near 52-week lows where the stock is broken but the business isn’t:

1. $PLTR | Palantir
2. $MSFT | Microsoft
3. $META | Meta
4. $SOFI | SoFi
5. $MELI | MercadoLibre
6. $SE | Sea Limited
7. $UBER | Uber
8. $NFLX | Netflix
9. $MA | Mastercard
10. $GRAB | Grab

[TopSecretStocks 🤫 @topsecretstocks]

Full report coming this sunday as I added some companies:

$IBRX (ImmunityBio): Commercial-stage IL-15 immunotherapy platform
$NAUT (Nautilus Biotechnology): Next-generation single-molecule proteomics
$PRME (Prime Medicine): Prime Editing for precise gene correction
$RXRX (Recursion Pharmaceuticals): AI-powered TechBio drug discovery
$TEM (Tempus AI): Multimodal data and precision medicine platform
$ABCL (AbCellera Biologics): AI-enabled antibody discovery engine
$TWST (Twist Bioscience): Silicon-based DNA synthesis leader

[Stocker-Man @TheStockerMan]

This chart is exactly why I remain so confident in the long-term $HIMS thesis. (Everything to know heading into Q2)

Revenue has grown from $527M in 2022 to $2.35B in 2025.

That is approximately 345% total growth in only three years, with a revenue CAGR of roughly 64.5%.

But the more important part of this chart is the transition underneath the revenue growth.

In 2022, $HIMS generated a net loss of approximately 66M.

In 2023, that loss narrowed to approximately 24M.

In 2024, the business reached full-year profitability with $126M in net income.

And in 2025, net income remained positive at approximately $128M while revenue increased another 59%.

At first glance, the decline in net margin from approximately 9% to 5% may look concerning.

But there is important context.

The 2024 result included a roughly $54M income-tax benefit, largely related to the release of a deferred-tax valuation allowance. That provided a significant boost to 2024 net income that did not repeat at the same level in 2025.

Meanwhile, $HIMS was investing heavily in customer acquisition, technology, fulfillment capacity, international expansion and new product categories.

Marketing increased 35%.

Technology and development spending increased 89%.

Operations and support spending increased 54%.

General and administrative expenses increased 63%.

Despite all of that investment, adjusted EBITDA increased from approximately $177M to $318M, with adjusted EBITDA margin improving from 12% to 14%.

That tells me the core platform continued becoming more profitable, even though the GAAP net-margin line declined.

Now, Q2 and Q3 of 2026 become extremely important.

Q1 showed the impact of the GLP-1 reset clearly:

Revenue grew only 4% YoY to 608M.

Gross margin declined from 73% to 65%.

The company recorded a $92M net loss.

Adjusted EBITDA fell from $91M to 44M.

I will be watching whether Q2 and Q3 show:

Revenue growth reaccelerating after the GLP-1 transition.

Gross margins beginning to stabilize.

Adjusted EBITDA recovering.

Subscriber growth continuing.

The new branded weight-loss model gaining traction.

International expansion and newer categories beginning to contribute.

I do not need margins to immediately return to their previous peak.

I need evidence that the Q1 pressure was transitional rather than structural.

If $HIMS can return to stronger growth while gradually rebuilding gross margin, adjusted EBITDA and free cash flow, the long-term thesis remains fully intact.

I believe $HIMS has the potential to become a 10x investment over the long term.

I am investing in the possibility that $HIMS becomes one of the largest personalized healthcare platforms in the world.

Q2 and Q3 should tell us a lot about whether the next stage of that thesis is beginning.

[Antonio Linares @alc2022]

biology drives most market returns over the next decade. my bio/acc basket:

$naut reads proteomic source code
$rxrx AI-designs the optimal drug per person
$ibrx is thr machine that fixes your immune system
$inkt makes immunotherapy work on solid tumors

[Antonio Linares @alc2022]

$DUOL is a $600 stock today

[mon @moninvestor]

In the long run, I believe $HIMS can get to 100 million subscribers.

You can see from this slide that Hims ambition is to help over 100 million consumers across the specialties and regions it serves.

Look at the table today. They currently have six specialties, spanning:

- weight loss
- sexual health
- dermatology
- mental health
- hormone health
- labs

Across five regions with a combined adult population of more than 600 million (US 250M+, Europe 200M+, Japan 100M+, Canada 30M+, Australia 20M+).

The real opportunity is in how little of that grid is switched on. In the US, all six specialties are live. Almost everywhere else, only one or two are.

- Canada and Japan are essentially just weight loss.
- Europe is still missing mental health and labs.
- Australia and Japan have only just come online through the Eucalyptus acquisition that closed on 2 June 2026.

Every empty cell in that matrix is a specialty Hims has already built in the US and can roll straight into a new market.

And the demand is barely tapped. In some of these conditions, as much as 90% of the applicable population has never sought treatment at all. So this is not a fight for share in a crowded market (I believe there will be more than one winners). It is about reaching enormous numbers of people who are not being treated today.

Growth: The company grows in two directions at once, and they compound:

1. The first is geographic - Take a specialty that already works in the US and switch it on in a new country.

2. The second is by category - Add a new specialty and every region it touches gets larger overnight.

Because the company runs one platform, one supply chain and one subscription relationship with each customer, each new specialty is mostly added on top of infrastructure that already exists, rather than built from scratch.

That is the real engine behind the total addressable market. Every specialty Hims adds widens the top of the funnel, because it gives an existing customer another reason to stay and a new customer a reason to join.

Someone who arrives for weight loss can later add dermatology, then labs, then hormone health, all inside the same monthly relationship.

The same person counts once today, but over time represents several subscriptions worth of revenue. As the menu grows, the average customer touches more of it and the lifetime value of each subscriber climbs alongside the subscriber count.

Now layer the categories Hims has signalled it wants to move into next, from longevity and preventive health to peptides and broader primary care. Each of those categories are large, recurring and largely cash pay, and they map onto needs almost everyone has at some point in their life.

So the math to 100 million is not about one product going viral. It is six specialties becoming ten or twelve, five regions becoming filled in rather than mostly blank, and a population where the majority has never been treated finally being reached.

They have roughly 2.6 million subscribers today. Set that against a grid that is mostly empty, a category list that is still growing and a 90% untreated population, and the ceiling is far higher than the current number suggests.

That is the long-term map and I believe the company is just getting started.

[Stocker-Man @TheStockerMan]

My current long-term holding allocation with their current share price as of today:

$TSLA 24% (397$)
$SOFI 15% (18$)
$AMD 15% (216$)
$HIMS 10% (15$)
$OSCR 9% (12$)
$ZETA 7% (15$)
$PLTR 6% (130$)
$NBIS 5% (100$)
$LMND 5% (50$)
$PATH 4% (10$)

I’m not selling a single share of any of these before 2031 unless my long-term thesis changes.

I’m aiming for 4–10x by 2031 across this basket, with a couple names having real 10x+ upside.

[The Tech Investor @TheTechInvest]

Someone is buying these stocks aggressively:

1. $NVDA
2. $META
3. $MSFT
4. $AVGO
5. $IREN
6. $CRWV
7. $MU
8. $SNDK
9. $CRDO
10. $BTDR

[Dimitris Mathianakis @dimatecon]

@Ashton_1nvests If $LULU manages to even return to low single-digit growth (5%-8%) and recover some of the margins, the upward repricing could be very large.

[Dimitris Mathianakis @dimatecon]

@Ashton_1nvests Ashton make a comment please about Lululemon that today results. How doyou like the growth?

[Dimitris Mathianakis @dimatecon]

@Ashton_1nvests I don't see:
brand collapse
sales collapse
balance sheet problem The most interesting thing for me is not the earnings or sales. It's that the stock is now trading at about 11-12 times expected 2026 earnings (~$11 EPS).

[Dimitris Mathianakis @dimatecon]

@StockSavvyShay Bundey 800MW announcement

🟢 Russell 3000 inclusion

🟢 $3.6B GPU financing

🟢 NVIDIA / Blackwell narrative

🟢 αυξανόμενη πεποίθηση ότι η IREN μετατρέπεται σε AI infrastructure company

[Dimitris Mathianakis @dimatecon]

@StockSavvyShay Bundey 800MW announcement

🟢 Russell 3000 inclusion

🟢 $3.6B GPU financing

🟢 NVIDIA / Blackwell narrative

🟢 αυξανόμενη πεποίθηση ότι η IREN μετατρέπεται σε AI infrastructure company

[Shay Boloor @StockSavvyShay]

$IREN just announced plans to develop an 800MW data center campus in Bundey, Australia.

The project marks IREN’s first announced data center development in Australia and expands its AI infrastructure footprint.

[Daniel @danielisdizzy]

These stocks are wealth generation opportunities:
• $SOFI at $18
• $NVO at $45
• $CRWV at $108
• $HIMS at $26
• $IREN at $63
• $LMND at $58
• $GRAB at $3
• $META at $632
• $ROOT at $51
• $ETH at $2K

[The Tech Investor @TheTechInvest]

Potential 10X watchlist for the coming pullback:

1. $IREN
2 $EOS.ASX
3. $BTDR
4. $TE
5. $NBIS
6. $WULF
7. $APLD
8 $CIFR
9. $LITE
10. $BE
11. $AAOI
12. $CRDO
13. $ACMR
14. $KTOS
15. $OSCR
16. $HIMS

[HedgeMind @HedgeMind]

$ZS | Hedge Funds Turned Bearish

Top hedge funds were net sellers of $ZS in Q1.

📉 Our data also shows:
➣ The total number of hedge fund holders has declined steadily over the last 3 quarters
➣ Hedge fund participation continues trending lower

➡️ A signal that conviction among elite managers has been weakening over time.

Discover more hedge fund insights:
https://t.co/EN3fwyn0PG

[Daniel @danielisdizzy]

One of my favorite signals in the market:

Buying stocks below CEO purchase prices.

• $SOFI CEO bought $1M worth of shares at $17.88, another $500K at $17.32, then another $500K split between $15.73 and $16.00. Today, $SOFI trades at $15.57.

• $NOW CEO bought $3M at $105, saying the stock can 10x from here. Today, the stock trades at $101.

• $NKE CEO and Tim Cook each bought $1M at $42 (after previously buying around ~$60). Today, the stock trades at $42.

• $HIMS repurchased $80M worth of shares in Q4 at an average price of $39 because management considered it undervalued. Today, the stock trades at $23.

Insiders sell for many reasons.

They buy for one.

CEO buying activity is one of the strongest signals investors can track.

[Dimitris Mathianakis @dimatecon]

@macro_guru The bank charter for Upstart is likely:
the biggest potential positive catalyst of the next 3 years, but also,the company's biggest execution/regulatory wildcard.

[Daniel @danielisdizzy]

My favorite risk/reward setups in the market right now:

AI / Compute:
• $IREN at $56
• $CIFR at $21
• $CRWV at $104

Fintech:
• $SOFI at $15
• $HOOD at $73

Healthcare:
• $HIMS at $23
• $NVO at $44

Quality:
• $META at $607
��� $AMZN at $265

Insurance:
• $LMND at $56
• $ROOT at $57